A Phase 2 Study to Evaluate the Safety and Immunogenicity of a Recombinant HIV Type 1 Vaccine Based on Adeno-Associated Virus. AIDS Res Hum Retroviruses, 26, 933-942. presented at the 08/2010. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20666584. (2010).
Studies of a Prophylactic HIV-1 Vaccine Candidate Based on Modified Vaccinia Virus Ankara (MVA) with and without DNA Priming: Effects of Dosage and Route on Safety and Immunogenicity. Vaccine, 25, 2120-2127. presented at the 03/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17250931. (2007).
Phase 2A Dose and Route Study of a DNA Prime MVA Boost Vaccine Candidate. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.. (2005).
Safety and Immunogenicity of MVA.HIVA by 3 Different Routes. In AIDS Vaccine 2005 International Conference. presented at the 06/09/2005, Montreal, Quebec, Canada.. (2005).